Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
fda
5
×
life sciences
national blog main
5
×
san francisco blog main
biotech
cancer
national top stories
san francisco top stories
blueprint medicines
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
loxo oncology
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
deals
eli lilly
europe blog main
investing
larotrectinib
american society of clinical oncology (asco)
anti-inflammatory drugs
What
cancer
5
×
drug
5
×
fda
biotech
marketing
medicine
medicines
new
targets
ahead
ambien
american
annual
approval
approved
asco
attendees
attention
black
blueprint
camp’s
candidate
cash
chicago
city
clinic
clinical
combinations
community’s
companies
currently
days
deeper
diamond
dna
eisai
eluded
expanding
fingerprint
flags
Language
unset
Current search:
fda
×
drug
×
cancer
×
" national blog main "
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More